Monday, 11 Dec 2017

You are here

Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial

Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).

Previously, the SPIRT I trial demonstrated efficacy and safety of ixekizumab (IXE) in patients who were biologic DMARD-naive. In that 52-week study, 417 active PsA patients received either IXE 80 mg, IXE 40mg, adalumumab or placebo.  IXE patients showed significant improvement of arthritis, dactylitis and enthesitis along with impressive PASI 75 and PASI 90 results as well.

The current SPIRIT P2 trial assessed the efficacy of IXE in patient not responding to TNFi.  In this phase 3 trial, 363 adults with psoriatic arthritis were assigned (1:1:1) subcutaneous IXE 80 mg every 4 weeks or IXE every 2 weeks after a 160 mg starting dose or placebo. The primary endpoint was ACR-20 response at week 24.

At week 24, ACR-20 responses were higher with with IXE every 4 weeks (53%) and IXE every 2 weeks (48%) compared to placebo (20%).

Serious adverse events were low (3% IXE q4wk; 7% IXE q2wk; 3% placebo) and there were no deaths. Three (2%) serious infections, were seen in the IXE 2 weeks group.

Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixekizumab.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis

On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.

ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content - http://acr17.rheumnow.com/category/gout-crystal/

Specific items:

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.